Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWObeldesivir is an antiviral nucleoside analog and a prodrug form of GS-441524 (Item No. 30469).1 It inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV-2 Βeta, Gamma, or Omicron variants in infected Vero E6 cells (EC50s = 1.36, 1.127, 0.349, and 0.106 µM, respectively) with a 50% cytotoxicity concentration (CC50) value of 128 µM. Obeldesivir (250 or 500 mg/kg per day) reduces nucleocapsid guide RNA (gRNA) copy number and small-guide RNA (sgRNA) levels in the lungs of, and decreases lung damage in, a KI-hACE2 mouse model of SARS-CoV-2 infection. It reduces the levels of the spike glycoprotein (S protein), also known as the surface glycoprotein, in the lungs of, as well as decreases particle forming units (PFUs) in the lung tissues, reduces lung and spleen inflammation, and prevents viral infection-induced death in, a K18-hACE2 mouse model of SARS-CoV-2 infection when administered at doses of 100 or 250 mg/kg per day.
WARNING This product is not for human or veterinary use.
1. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-